Amivantamab
Amivantamab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Colorectal Neoplasms。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
22 项
全球在招研究
3 项
已进入 III/IV 期
30 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Janssen Research & Development, LLC
- National Cancer Institute (NCI)
- Groupe Francais De Pneumo-Cancerologie
- N-Power Medicine
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Gruppo Oncologico del Nord-Ovest
- Vall d'Hebron Institute of Oncology
- Fondazione Ricerca Traslazionale
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、中国、法国、德国、日本、Malaysia、Poland、South Korea、西班牙、中国台湾、英国、加拿大
正在招募患者的 Amivantamab 研究
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
I 期 / II 期招募中美国中国法国德国NCT06385080A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
II 期招募中美国加拿大中国South KoreaNCT07586202A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
不适用招募中奥地利比利时Czechia德国NCT07230691A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
I 期 / II 期招募中美国加拿大中国South KoreaNCT07227025Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System
II 期招募中美国NCT07042295Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion
不适用招募中法国NCT06247826A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
I 期 / II 期招募中美国比利时加拿大中国NCT05379595An External Control Arm Study in Non-Small Cell Lung Cancer
不适用招募中美国NCT07174388Amivantamab Combined With Intrathecal Pemetrexed for LM From EGFR-Mutated Lung Adenocarcinoma
I 期 / II 期招募中中国NCT07744529Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
II 期招募中意大利NCT05845450A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
III 期招募中美国澳大利亚比利时BrazilNCT06750094A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)
II 期招募中法国德国意大利荷兰NCT03767075Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations.
II 期招募中意大利NCT07392658Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
II 期招募中美国NCT06116682A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
III 期招募中美国澳大利亚奥地利比利时NCT07276399ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC
I 期招募中美国澳大利亚加拿大NCT06816992Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer
不适用招募中法国NCT07563205A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
II 期招募中美国Brazil中国法国NCT05498428Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)
II 期招募中比利时德国荷兰NCT06784791A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
III 期招募中美国比利时Brazil加拿大NCT06662786A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
I 期招募中美国South Korea西班牙NCT07107230A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
II 期招募中美国比利时芬兰法国NCT06667076
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。